A novel insulin unit calculator for the management of XXXX .

@entity1 @entity1723 @entity413 @entity1735
BACKGROUND: Intensive insulin therapy is the gold standard therapy for @entity1723 ( @entity1723 ) @entity1 . To achieve optimal glycemic control, adjustments of insulin dose at mealtimes must be made taking into account several parameters: blood @entity413 levels, insulin/ @entity1735 ratio, @entity1735 intake, and physical activity. Calsulin (Thorpe Products Ltd., Cambridge, UK) is a new tool for the administration of insulin dose before each meal. The aim of this study was to evaluate the efficacy of Calsulin on metabolic control in @entity1723 @entity1 undergoing intensive insulin therapy. SUBJECTS AND METHODS: Forty consecutive @entity1 affected by @entity1723 , 18-65 years old, with disease duration of >1 year, were randomized to Calsulin or to the control group. Hemoglobin A1c (HbA1c) was evaluated at entry into the study and at 3- and 6-month follow-ups. Paired t test (two tailed) and analysis of variance were used to evaluate differences in HbA1c at 3 and 6 months in the two groups. RESULTS: HbA1c at entry was 7.9    1.0% (SD) in the Calsulin-treated group and 7.8    1.6% (SD) in control @entity1 (P not significant). Data showed a slight improvement in HbA1c levels at 3 months in the Calsulin-treated group (-0.61% vs. -0.14% difference, respectively; P not significant). At the 6-month follow-up, a significant reduction in HbA1c levels was observed in the Calsulin-treated group versus the control group (-0.85% vs. -0.07% difference, respectively; P < 0.05). CONCLUSIONS: Calsulin is an acceptable and practical tool that makes the process of calculating insulin doses easy to use, and, most importantly, it improves metabolic control as shown by a significant reduction of HbA1c levels.
